Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
12 November, 2025
Veterans golf club swings behind TROG Cancer Research
LATEST NEWS: 12 November 2025 More than 100 golfers
6 November, 2025
SUPREMO trial findings signal change in breast cancer treatment
LATEST NEWS: 6 November 2025 Radiotherapy can be safely